Browse the evidence

The appropriate use of NB-ER should consider the specific characteristics and adiposity-related complications of an individual.

Practitioners should assess individual patient characteristics when prescribing NB-ER.

Tirzepatide has been approved by the FDA for treating T2D and managing chronic weight in overweight or obese patients.

Healthcare providers can confidently prescribe tirzepatide for eligible patients based on FDA approval.

The Mediterranean diet is advised for cardiovascular prevention in patients with familial hypercholesterolemia (FH).

Practitioners should consider recommending the Mediterranean diet to patients with FH.

Limiting dietary fat and saturated fatty acids is an advised strategy for managing familial hypercholesterolemia.

Practitioners should advise FH patients to limit dietary fat and saturated fatty acids.

Supplementation of phytosterols and fiber can be helpful in managing familial hypercholesterolemia.

Practitioners may consider recommending phytosterol and fiber supplements to FH patients.

Patients with obesity experienced a median weight change of -5% at 6 months and -4% at 18 months after the intervention.

Practitioners can expect significant weight loss in patients with obesity following a multicomponent lifestyle intervention.

Patients reported increased participation in physical activities by +1 day/week after the intervention.

Encouraging physical activity is essential in lifestyle interventions for obesity.

Nutritional counseling and remote monitoring led to a statistically significant reduction in the average consumption of products containing fats and salt among overweight and obese women.

Practitioners can implement nutritional counseling and remote monitoring to effectively reduce fat and salt intake in overweight and obese patients.

Weight loss interventions can improve reproductive outcomes in women.

Implementing weight loss strategies may enhance fertility treatment success.

Sugar-sweetened beverage consumption is independently associated with noncommunicable diseases.

Reducing sugar-sweetened beverage consumption may help mitigate the risk of noncommunicable diseases.

Patients on dialysis achieved a mean total body weight loss of 7.8% (SD 6.1) after being prescribed semaglutide.

Semaglutide may be an effective weight loss intervention for patients on dialysis.

Phase 2 trials of retatrutide report unprecedented weight reductions comparable to bariatric surgery.

Retatrutide may provide an effective alternative to surgical weight loss methods.

Weight loss was consistently larger in the incretin intervention groups than in placebo or lifestyle intervention comparators.

Incretin therapies may be more effective for weight loss compared to lifestyle changes or placebo.

Weight loss significantly explained heterogeneity in treatment effects on fibrosis improvement and MASH resolution.

Weight management should be emphasized in treatment plans for MASH to enhance treatment efficacy.

GLP-1 receptor agonist treatment is associated with a 10.3% reduction in fat mass (FM) at 6 months, 17.3% at 12 months, and 18.0% at 24 months.

GLP-1RA treatment leads to significant fat mass reduction over 24 months.

The study suggests that the combination of CC and WS may enhance weight loss in patients on a mildly hypocaloric diet.

This combination may be recommended as a supplement to support weight loss efforts in conjunction with dietary changes.

A significantly higher rate of patients from the pure Semaglutide group achieved the ten percent (50.54% vs. 44.64%) and fifteen percent (21.42% vs. 12.78%) weight loss thresholds compared to the compounded Semaglutide group.

Practitioners should note that pure Semaglutide may lead to better outcomes in achieving significant weight loss thresholds.

Lifestyle interventions that include diet, exercise, and behavioral modification have been the foundation for management of obesity.

Practitioners should prioritize lifestyle interventions in obesity treatment plans.

The American Gastroenterological Association recommended adding pharmacologic agents to lifestyle interventions for adults with obesity or overweight with weight-related complications who have had an inadequate response to lifestyle interventions alone.

Practitioners should consider pharmacologic options for patients not responding to lifestyle changes.

Surgical treatment of obesity achieves the greatest long-term weight loss compared to conservative treatment.

Practitioners should consider surgical options for patients seeking significant long-term weight loss.

The category of weight loss had significantly greater decreases in hunger and increases in flexible dietary restraint compared to the categories of weight stability and weight gain.

Weight loss may be associated with improved hunger management and dietary restraint.

Clinical trials have demonstrated effectiveness in lowering HbA1c and body weight.

Evidence from clinical trials supports the use of Tirzepatide for improving glycemic control and reducing body weight.

Patients experienced an average weight loss of 16.06 ± 7.6 pounds at 12 weeks and 38.82 ± 11.4 pounds at 24 weeks.

Practitioners can expect significant weight loss in patients using compounded GLP-1 ± GIP agonists.

Several newer anti-obesity medications (AOMs) have been shown to reduce body weight significantly.

Clinicians can consider newer AOMs as effective options for weight management in obese patients.